See more : Capgemini SE (CAP.SW) Income Statement Analysis – Financial Results
Complete financial analysis of Defence Therapeutics Inc. (DTCFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Defence Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Internet Initiative Japan Inc. (IIJIF) Income Statement Analysis – Financial Results
- Bougainville Copper Limited (BOC.AX) Income Statement Analysis – Financial Results
- Odyne Corporation (ODYC) Income Statement Analysis – Financial Results
- Primeserv Group Limited (PMV.JO) Income Statement Analysis – Financial Results
- Oie Sangyo Co., Ltd. (7481.T) Income Statement Analysis – Financial Results
Defence Therapeutics Inc. (DTCFF)
About Defence Therapeutics Inc.
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 13.82K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -13.82K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.86M | 3.58M | 3.76M | 1.16M | 433.45K | 0.00 |
| General & Administrative | 1.25M | 641.39K | 1.04M | 1.36M | 239.73K | 41.95K |
| Selling & Marketing | 1.71M | 1.96M | 2.52M | 341.10K | 0.00 | 41.90K |
| SG&A | 8.79M | 2.90M | 3.56M | 1.70M | 239.73K | 41.95K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.66M | 6.48M | 7.32M | 2.86M | 673.18K | 41.95K |
| Cost & Expenses | 12.66M | 6.48M | 7.32M | 2.86M | 673.18K | 41.95K |
| Interest Income | 0.00 | 6.81K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 262.93K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 70.94K | 13.82K | 7.27M | 2.83M | 673.18K | 41.95K |
| EBITDA | -12.68M | -6.48M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.66M | -6.48M | -7.30M | -2.86M | -673.18K | -41.95K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -537.24K | -387.15K | -70.18K | 0.00 | 0.00 | 40.00K |
| Income Before Tax | -13.19M | -6.87M | -7.34M | -2.86M | -673.18K | -1.95K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 105.00K | 16.59K | -1.16M | -434.13K | -41.95 |
| Net Income | -13.19M | -6.76M | -7.34M | -2.86M | -673.18K | -1.95K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.30 | -0.17 | -0.20 | -0.11 | -0.02 | 0.00 |
| EPS Diluted | -0.30 | -0.17 | -0.20 | -0.11 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 44.63M | 39.66M | 36.08M | 26.60M | 34.80M | 34.80M |
| Weighted Avg Shares Out (Dil) | 44.63M | 39.66M | 36.08M | 26.60M | 34.80M | 34.80M |
Defence Provides Update on Delivery of AGSM Proxy Materials
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in...
Defence's Proprietary Accum Technology Ready to License to Companies Developing Antibody Drug Conjugates (ADC)
Vancouver, British Columbia--(Newsfile Corp. - November 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in...
Defence Announces Dr. Maxime Parisotto as CSO, Director of Science and Business Development
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in...
Defence Announces Closing of Securities for Debenture Financing
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in...
Defence Therapeutics Announces Securities for Debenture Financing
Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in...
Defence Announces Radiopharmaceutical Expert Svetlana Selivanova Joins Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - November 13, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in...
Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition...
Defence Therapeutics Completes 1st Tranche of Financing
Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the...
Defence's Corporate Updates, Arranges Financing
Vancouver, British Columbia--(Newsfile Corp. - September 27, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and novel immune-oncology vaccines and drug delivery technologies, is pleased to give...
Defence Appoints New Interim Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), announces that Kwin Grauer has been appointed interim Chief Executive Officer replacing Sébastien Plouffe as President and Chief...
Source: https://incomestatements.info
Category: Stock Reports